Decipher Labs (BSE: DECIPHER) is loss-making over the last 12 months, losing ₹1.84 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹5.70, 48% below its 52-week high. Sales fell 32% a year over 3 years. The company has almost no debt. It is a small-cap company with a market cap of ₹5.76 Cr, ranked 154th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 41% over the past year.
- ₹5.06
- ₹5.78
- ₹5.06
- ₹5.79
- 7.6K
Health check
- ReturnsBehind
−41.1% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthShrinking
Sales −32.4% a year over 3 years.
- ProfitabilityNegative
ROCE -15.6% vs peer median 17.9%.
- Balance sheetStretched
Practically debt-free, Piotroski 3 of 9.
- Red flags4 to check
Loss-making over the last twelve months.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹5.76 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- 0.28
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- −14.2%
- Peers 14.7%
- ROCE
- −15.6%
- Peers 17.9%
- Debt to equity
- 0.02
- Debt ₹0.50 Cr
- EPS (TTM)
- −₹3.02
- OPM (TTM)
- −16.4%
- Net margin −13.3%
- Sales growth
- −17.4%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 0.42
- EV/EBITDA −2.9
Strengths and risks
Strengths
- Practically debt-free.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −14.2%.
- Quarterly sales down 17.4% on a year ago.
- 48% below its 52-week high.
About Decipher Labs
Decipher Labs Limited, together with its subsidiaries, manufactures, markets, sells, and trades in pharmaceutical drugs in India and internationally. It operates through two segments, Manufacturing and Trading of Pharmaceutical Drugs and Consultancy. The company offers branded and finished formulations, bulk drugs, and chemicals. It also provides information technology (IT) consultancy services comprising technology integration and systems consulting,…
- Headquarters
- Hyderabad
- Employees
- 1
- Sector
- Healthcare
- ISIN
- INE643N01012
- Website
- decipherlabs.in
Price range
- Avg volume (3M)
- 3.9K
- 1-year return
- minus 41.1%
- From 52-week high
- minus 48.1%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| DECIPHERDecipher Labs | 5.70 | minus 1.55% | 6 | – | 0.28 | −15.6% | −14.2% | −16.4% | −32.4% | – | 0.00% | minus 41.1% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 2.9 | 4.3 | 3.2 | 3.6 | 2.4 | |
| 6.2 | 4.2 | 3.6 | 3.4 | 4.6 | |
| −3.3 | 0.1 | −0.4 | 0.2 | −2.2 | |
| −113.4% | 2.9% | −13.2% | 6.3% | −89.2% | |
| 0 | 0 | 0 | 0.2 | 0.1 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| −3.4 | 0 | −0.5 | 0.3 | −2.2 | |
| −0.1% | −6.3% | −1.1% | −242.2% | 0.0% | |
| −3.4 | 0 | −0.5 | 0.9 | −2.2 | |
| -3.39 | 0.02 | -0.53 | -0.35 | -2.16 |
Profit & loss
- Sales CAGR 3Y
- −32.4%
- ROE
- −14.2%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 45.6 | 35.9 | 22.6 | 14.1 | |
| – | minus 21.3% | minus 37.0% | minus 37.8% | |
| 47 | 35.4 | 23.9 | 16.8 | |
| −1.4 | 0.5 | −1.3 | −2.7 | |
| −3.1% | 1.4% | −5.8% | −19.2% | |
| 6.5 | 0 | 0.9 | −0.2 | |
| 0.4 | 0.2 | – | – | |
| 0.4 | 0.5 | 0.4 | 0.5 | |
| −8.4 | −1.1 | −5.6 | −0.3 | |
| −4.2 | −1.2 | −6.4 | −3.7 | |
| 35.5% | −38.4% | 20.5% | 16.3% | |
| −2.7 | −1.7 | −5.1 | −3.1 | |
| -2.66 | -1.66 | -5.03 | -3.05 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 10.1 | 10.1 | 10.1 | 10.1 | |
| 13.1 | 11.8 | 12.8 | 10.6 | |
| 0.9 | – | 0.2 | 0.5 | |
| 4 | 11.8 | 2.7 | 3.2 | |
| 28.2 | 33.6 | 25.8 | 24.3 | |
| 1 | 0.9 | 0.8 | 0.8 | |
| 3.8 | 0.3 | 0.3 | 0.3 | |
| 7.4 | 9.3 | 2.8 | 0.7 | |
| 16 | 23.2 | 21.9 | 22.5 | |
| 28.2 | 33.6 | 25.8 | 24.3 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −1.6 | 4.9 | −9.8 | −2.4 | |
| −4.3 | −1.8 | 3.1 | −0.2 | |
| −2.2 | −1.2 | 0.2 | −0 | |
| −8 | 1.9 | −6.5 | −2.7 | |
| −0.8 | −0.1 | −0.1 | −0.2 | |
| −2.3 | 4.8 | −9.9 | −2.7 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.